Company Filing History:
2 out of 10 
1 out of 5 
1 out of 2,012 
Years Active: 2002-2005
Title: Innovations by Jeff Hall in Pharmaceutical Metabolism
Introduction
Jeff Hall is an accomplished inventor based in Carlsbad, California. He has made significant contributions to the field of pharmacogenomics, particularly in the evaluation of how individuals metabolize pharmaceuticals. With a total of three patents to his name, Hall's work has the potential to impact the effectiveness of chemotherapeutic agents.
Latest Patents
One of Hall's latest patents focuses on methods for evaluating the ability to metabolize pharmaceuticals. This patent discloses methods for detecting variant genes that have a polymorphism associated with reduced metabolism of specific substrates, including CYP3A4 and CYP3A5. These genotyping methods are designed to identify polymorphisms linked to reduced metabolism of chemotherapeutic agents such as cyclophosphamide and BCNU. Additionally, Hall has developed novel polymorphic nucleic acid molecules that are useful in these methods. Another significant patent involves genetic typing of the human cytochrome P450 2A6 gene. This patent reveals novel polymorphisms in the gene and discusses their use as predictive sequences for altered metabolism or the occurrence of disease.
Career Highlights
Throughout his career, Jeff Hall has worked with notable companies in the biotechnology sector. He has been associated with Genaissance Pharmaceuticals, Inc. and Dna Sciences Laboratories, Inc. His work in these organizations has allowed him to advance his research and contribute to the understanding of genetic factors in drug metabolism.
Collaborations
Hall has collaborated with several professionals in his field, including Marco Guida and William P. Petros. These collaborations have likely enriched his research and expanded the impact of his inventions.
Conclusion
Jeff Hall's innovative work in the field of pharmacogenomics has led to important advancements in understanding how genetic variations affect drug metabolism. His patents reflect a commitment to improving therapeutic outcomes for patients through personalized medicine.